NCT05918627

A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

A Randomized, Double-blind, Placebo-controlled, Dose Escalating Study to Examine the Safety, Tolerability and Pharmacokinetic Profile of Single Oral Doses of SLx-2119 in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Kadmon, a Sanofi Company · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple doses of SLx-2119 in healthy male participants.

Detailed description

Duration per participants is Day 1 up to 30 days after participant is treated with the last dose of study drug.

Conditions

• Immune System Disorder (Healthy Volunteer)

Interventions

Type	Name	Description
DRUG	Belumosudil mesylate	Pharmaceutical form: capsule; Route of administration: oral
DRUG	Placebo	Pharmaceutical form: capsule; Route of administration: oral

Timeline

• Start date: 2009-09-21
• Primary completion: 2009-12-09
• Completion: 2009-12-09
• First posted: 2023-06-26
• Last updated: 2023-06-26

Locations

1 site across 1 country: United States